ABT-450/r-ombitasvir and dasabuvir with ribavirin eliminates viraemia in most patients with HCV infection with cirrhosis

Valérie Martel-Laferrière

Microbiologie et Maladies Infectieuses, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montréal, Québec, Canada

Correspondence to: Dr Valérie Martel-Laferrière, Microbiologie et Maladies Infectieuses, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, 1058 rue Saint-Denis, Montréal, Québec, Canada H2X 3J4; valerie.martel-laferriere@umontreal.ca


Context
The prevalence of hepatitis C virus (HCV) reached its peak in 1994 and is expected to decrease significantly over the next few years. However, HCV-related cirrhosis continues to increase. Razavi et al predicted that decompensated cirrhosis will reach its peak in 2019. This translates into increased healthcare costs secondary to complications of cirrhosis.

Patients with cirrhosis due to HCV infection are less likely to achieve a sustained virological response (SVR), even in the era of direct-acting antivirals (DAAs). Only 62% of genotype-3 cirrhotics treated with sofosbuvir and ribavirin for 24 weeks achieved SVR compared with 87% of non-cirrhotics. Treatment of advanced cirrhosis brings increased risks of complications.

As fewer cirrhotics are generally included in interferon-free trials, expected outcomes are extrapolated from a small number of participants. Poordad and colleagues explored rates of SVR and adverse events associated with ABT-450/r-ombitasvir, dasabuvir and ribavirin among a cohort of exclusively patients with cirrhosis.

Methods
This randomised controlled trial included 380 patients with Child-Pugh class-A cirrhosis. Patients were given protease inhibitor ABT-450 boosted with ritonavir, the NSSA inhibitor ombitasvir, the non-nucleoside polymerase inhibitor dasabuvir and ribavirin (3D-RBV regimen) for 12 or 24 weeks. Both previously untreated and treated patients were included, but patients with prior exposure to DAAs were excluded. Patients were classified by their treatment history. Untreated patients were additionally stratified by HCV subgenotype and IL28B genotype. Treated patients were separated by HCV subgenotype and previous treatment response.

The primary endpoint was SVR 12 weeks after end of treatment. The authors ascertained non-inferiority and superiority of the 12-week and 24-week groups against the estimated historical control group (telaprevir-based regimen; 47%, 95% CI 41% to 54%). The comparison between the 12-week and 24-week SVR rates was the key secondary endpoint. The percentage of patients with virological failure and relapse was also determined in each treatment arm. Modified intent-to-treat analysis was performed.

Findings
In the 12-week arm, 91.8% (97.5% CI 87.6% to 96.1%) of participants achieved SVR 12, compared with 95.9% (97.5% CI 92.6% to 99.3%) in the 24-week arm. These results met non-inferiority and superiority to historical controls. Superiority was demonstrated among all subgroups, including prior null responders. SVR rate difference between the 12-week and 24-week arms did not reach statistical significance (p=0.09). Prior null-response to pegylated-interferon/ribavirin treatment, subgenotype 1a and self-reported history of injection-drug use were associated with lower likelihood of SVR in multivariable logistic regression.

Virological failure occurred in 0.5% and 1.7% patients of the 12-week and 24-week arms, respectively. Relapses were more common in the 12-week arm (5.9% vs 0.6%). Overall, 15 of the 17 patients who failed or relapsed had resistance-associated mutations to at least two drug targets.

Adverse events were common (91.3%), but only 8 patients (2.1%) discontinued as a result, with 21 patients (5.5%) experiencing serious adverse events. Severe anaemia (grades 3–4) occurred in 1.1% of patients. Grades 3–4 total hyperbilirubinaemia was the most common laboratory abnormality (9.7%).

Competing interests VM-L has lectured for Gilead Sciences.

Provenance and peer review Commissioned; internally peer reviewed.

References
ABT-450/r-ombitasvir and dasabuvir with ribavirin eliminates viraemia in most patients with HCV infection with cirrhosis
Valérie Martel-Laferrière

Evid Based Med 2015 20: 6 originally published online September 10, 2014
doi: 10.1136/ebmed-2014-110055

Updated information and services can be found at:
http://ebm.bmj.com/content/20/1/6

These include:

References
This article cites 5 articles, 0 of which you can access for free at:
http://ebm.bmj.com/content/20/1/6#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Clinical trials (epidemiology) (1594)
- Health economics (124)
- Health policy (216)
- Health service research (176)
- Hepatitis (sexual health) (27)
- Hepatitis and other GI infections (27)
- Liver disease (55)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/